Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Adult Volunteers and Patients With Hereditary Angioedema Predicts Similar Exposure in Adolescent PatientsSmith MD, Rodgers T, Sharman J, Mutch P, Tachdjian R, Savic S, Farrell C
EAACI 2022
Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary AngioedemaAygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD
EAACI 2022
Oral factor XIIa inhibition blocks angiotensin converting enzyme inhibitor induced angioedema in mouseClermont AC, Murugesan N, Feener EP
KININ 2022
Oral FXIIa inhibitor KV998086 suppresses FXII zymogen mediated kallikrein kinin system activationMurugesan N, Lee DK, Duckworth EJ, Smith SA, Clermont AC, Hampton SL, Feener EP
KININ 2022
Oral sebetralstat (KVD900) provides rapid inhibition of the kallikrein kinin system in patients with hereditary angioedemaDuckworth EJ, Lee DK, Murugesan N, Rushbrooke L, Hampton SL, Smith M, Yea C, Audhya P, Feener EP
KININ 2022
KONFIDENT Phase 3 Trial Design for Sebetralstat (KVD900), a Novel Investigational Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angloedema AttacksLumry WR, Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA, Audhya PK, Smith MD, Yea CM, Riedl MA, Maurer M
EAC 2022
Agreement Between Improvements in Patient Global Impression of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial With Sebetralstat (KVD900) in Patients With Hereditary AngioedemaAudhya P, Smith MD, Williams P, Yea CM, Cohn DM
EAC 2022
Oral Sebetralstat (KVD900) Provides Rapid Inhibition of Plasma Kallikrein and Fast Improvement in Attack Symptoms in Patients With Hereditary AngioedemaSmith MD, Duckworth EJ, Hampton SL, Yea CM, Audhya P, Feener EP
EAC 2022
Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary AngioedemaAudhya P, Williams P, Yea C, Cohn D
AAAAI 2022
Rapid Plasma Kallikrein Inhibition Following Oral KVD900 Is Associated With Early Symptom Relief in Patients With Hereditary AngioedemaDuckworth EJ, Feener EP, Yea CM, Audhya P, Hampton SL, Smith MD
AAAAI 2022
